JP2014503555A - 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 - Google Patents

血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 Download PDF

Info

Publication number
JP2014503555A
JP2014503555A JP2013549502A JP2013549502A JP2014503555A JP 2014503555 A JP2014503555 A JP 2014503555A JP 2013549502 A JP2013549502 A JP 2013549502A JP 2013549502 A JP2013549502 A JP 2013549502A JP 2014503555 A JP2014503555 A JP 2014503555A
Authority
JP
Japan
Prior art keywords
vegf antagonist
dose
administered
vegf
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013549502A
Other languages
English (en)
Japanese (ja)
Inventor
ジョージ・ディー・ヤンコーポラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014503555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2014503555A publication Critical patent/JP2014503555A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2013549502A 2011-01-13 2012-01-11 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 Withdrawn JP2014503555A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161432245P 2011-01-13 2011-01-13
US61/432,245 2011-01-13
US201161434836P 2011-01-21 2011-01-21
US61/434,836 2011-01-21
US201161561957P 2011-11-21 2011-11-21
US61/561,957 2011-11-21
PCT/US2012/020855 WO2012097019A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202169A Division JP2017061467A (ja) 2011-01-13 2016-10-14 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用

Publications (1)

Publication Number Publication Date
JP2014503555A true JP2014503555A (ja) 2014-02-13

Family

ID=45507924

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013549502A Withdrawn JP2014503555A (ja) 2011-01-13 2012-01-11 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2016202169A Pending JP2017061467A (ja) 2011-01-13 2016-10-14 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2019104939A Pending JP2019167366A (ja) 2011-01-13 2019-06-05 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2021146749A Pending JP2021193115A (ja) 2011-01-13 2021-09-09 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2023174006A Active JP7733706B2 (ja) 2011-01-13 2023-10-06 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2025136675A Pending JP2025169389A (ja) 2011-01-13 2025-08-20 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2016202169A Pending JP2017061467A (ja) 2011-01-13 2016-10-14 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2019104939A Pending JP2019167366A (ja) 2011-01-13 2019-06-05 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2021146749A Pending JP2021193115A (ja) 2011-01-13 2021-09-09 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2023174006A Active JP7733706B2 (ja) 2011-01-13 2023-10-06 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JP2025136675A Pending JP2025169389A (ja) 2011-01-13 2025-08-20 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用

Country Status (13)

Country Link
US (14) US9254338B2 (enExample)
EP (4) EP2663325A1 (enExample)
JP (6) JP2014503555A (enExample)
KR (8) KR20200077622A (enExample)
CN (1) CN103533950A (enExample)
AU (5) AU2012205599B2 (enExample)
BR (1) BR112013017752A8 (enExample)
CA (1) CA2824422A1 (enExample)
HK (1) HK1244693A1 (enExample)
IL (3) IL295359A (enExample)
MX (3) MX349901B (enExample)
SG (4) SG10201509193UA (enExample)
WO (1) WO2012097019A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506589A (ja) * 2015-02-26 2018-03-08 フェラムダ リミテッド 血管形成疾患および障害を治療するための組成物および組み合わせ
JP2019516769A (ja) * 2016-05-25 2019-06-20 参天製薬株式会社 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用
JPWO2020241660A1 (enExample) * 2019-05-28 2020-12-03
JP2021509912A (ja) * 2018-03-16 2021-04-08 ノバルティス アーゲー 眼疾患を治療するための方法
WO2022186335A1 (ja) * 2021-03-03 2022-09-09 学校法人自治医科大学 副作用の予測方法およびそのための装置

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
HUE057653T2 (hu) * 2014-12-11 2022-05-28 Bayer Healthcare Llc Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017046140A1 (en) * 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
US20180353464A1 (en) * 2015-11-24 2018-12-13 Indiana University Research And Technology Corporation Composition for blocking angiogenesis
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CA3043487A1 (en) 2016-11-21 2018-05-24 Just-Evotec Biologics Inc Aflibercept formulations and uses thereof
EP3573641A4 (en) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019099786A1 (en) * 2017-11-16 2019-05-23 Ophthotech Corporation A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
AU2018375398C1 (en) * 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2019154776A1 (en) * 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
AU2020345174A1 (en) * 2019-09-12 2022-03-31 Lupin Limited Modified dosing of VEGF inhibitors for ophthalmic use
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization
KR20220110555A (ko) 2019-12-06 2022-08-08 리제너론 파마슈티칼스 인코포레이티드 Vegf 미니-트랩 및 그의 사용 방법
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
CA3180401A1 (en) * 2020-06-11 2021-12-16 Bartosz SIKORSKI Methods of improving retina-associated disease outcome using ccr3-inhibitors
US20240238427A1 (en) * 2021-04-14 2024-07-18 Kodiak Sciences Inc. Methods of treating an eye disorder
PL4185318T3 (pl) * 2021-05-17 2026-01-12 Regeneron Pharmaceuticals, Inc. Rozszerzone schematy leczenia dużymi dawkami antagonistów vegf w leczeniu angiogennych zaburzeń oka
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024168252A2 (en) * 2023-02-10 2024-08-15 Yale University Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy
JP2025003405A (ja) * 2023-06-23 2025-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 眼内血管新生性疾患の治療のための、ｖｅｇｆアンタゴニストの延長された高用量レジメン
WO2025036488A1 (en) * 2023-08-17 2025-02-20 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating age-related macular degeneration and diabetic macular edema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509369A (ja) * 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド 加齢黄斑変性症を処置するための方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
HRP20040406A2 (en) 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
JP2003309411A (ja) 2002-04-17 2003-10-31 Alps Electric Co Ltd 複合アンテナ
WO2004072320A2 (en) 2003-02-07 2004-08-26 Pavco, Inc. Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths
ATE354592T1 (de) 2003-03-28 2007-03-15 Regeneron Pharma Vegf-antagonisten zur behandlung von diabetes
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
MXPA05008973A (es) 2003-05-28 2006-02-22 Regeneron Pharma Metodo de tratamiento de rechazo de trasplante de cornea.
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
ATE507240T1 (de) 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
PL1767546T3 (pl) 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
CN1968709A (zh) 2004-06-18 2007-05-23 瑞泽恩制药公司 用于治疗恶性胸腔积液的vegf抑制剂
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
EP1802334B1 (en) 2004-10-21 2012-08-29 Genentech, Inc. Method for treating intraocular neovascular diseases
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
NZ721607A (en) 2014-01-25 2017-05-26 Chengdu Kanghong Biotechnologies Co Ltd Fusion protein inhibiting angiogenesis or growth and use thereof
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
AU2018375398C1 (en) 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509369A (ja) * 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド 加齢黄斑変性症を処置するための方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
OPHTHALMOLOGY, 2006, 113(9), P.1522.E1-1522.E14, JPN6015041135, ISSN: 0003174252 *
REGENERON, PRESS RELEASES, "VEGF TRAP-EYE FINAL PHASE 2 RESULTS IN AGE-RELATED MACULAR DEGENERATION, JPN6015041132, ISSN: 0003174251 *
ＲＥＧＥＮＥＲＯＮ，ＰＲＥＳＳ ＲＥＬＥＡＳＥＳ，″ＢＡＹＥＲ ＡＮＤ ＲＥＧＥＮＥＲＯＮ ＲＥＰＯ, JPN6017000536, ISSN: 0003478378 *
ＲＥＧＥＮＥＲＯＮ，ＰＲＥＳＳ ＲＥＬＥＡＳＥＳ，″ＲＥＧＥＮＥＲＯＮ ＡＮＤ ＢＡＹＥＲ ＲＥＰＯ, JPN6017000537, ISSN: 0003478379 *
ＶＩＥＷ ＯＦ ＮＣＴ００５０９７９５ ＯＮ ２００９＿１２＿０１，［ＯＮＬＩＮＥ］，２００９．１２, JPN6017000538, ISSN: 0003478380 *
ＶＩＥＷ ＯＦ ＮＣＴ００５０９７９５ ＯＮ ２０１１＿０１＿０７［ＯＮＬＩＮＥ］，２０１１．０１．, JPN6017000539, ISSN: 0003478381 *
ＶＩＥＷ ＯＦ ＮＣＴ００７８９４７７ ＯＮ ２０１０＿１１＿１８（［ＯＮＬＩＮＥ］，２０１０．１１, JPN6017000540, ISSN: 0003478382 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506589A (ja) * 2015-02-26 2018-03-08 フェラムダ リミテッド 血管形成疾患および障害を治療するための組成物および組み合わせ
JP2019516769A (ja) * 2016-05-25 2019-06-20 参天製薬株式会社 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
JP2021509912A (ja) * 2018-03-16 2021-04-08 ノバルティス アーゲー 眼疾患を治療するための方法
JP2021191778A (ja) * 2018-03-16 2021-12-16 ノバルティス アーゲー 眼疾患を治療するための方法
JP2024042697A (ja) * 2018-03-16 2024-03-28 ノバルティス アーゲー 眼疾患を治療するための方法
JPWO2020241660A1 (enExample) * 2019-05-28 2020-12-03
JP7561433B2 (ja) 2019-05-28 2024-10-04 学校法人順天堂 糖尿病網膜症の予防又は治療薬
WO2022186335A1 (ja) * 2021-03-03 2022-09-09 学校法人自治医科大学 副作用の予測方法およびそのための装置

Also Published As

Publication number Publication date
US11986511B2 (en) 2024-05-21
US20190046609A1 (en) 2019-02-14
US20240123030A1 (en) 2024-04-18
JP2021193115A (ja) 2021-12-23
US20220273764A1 (en) 2022-09-01
US11559564B2 (en) 2023-01-24
EP4360709A2 (en) 2024-05-01
SG10201509193UA (en) 2015-12-30
SG10202111177VA (en) 2021-11-29
US10828345B2 (en) 2020-11-10
BR112013017752A8 (pt) 2018-01-09
US20170202911A1 (en) 2017-07-20
HK1244693A1 (en) 2018-08-17
JP2024001190A (ja) 2024-01-09
US9669069B2 (en) 2017-06-06
NZ612593A (en) 2015-03-27
JP2017061467A (ja) 2017-03-30
JP2025169389A (ja) 2025-11-12
EP4360709A3 (en) 2024-07-03
US20130295094A1 (en) 2013-11-07
US20250152669A1 (en) 2025-05-15
AU2012205599A1 (en) 2013-07-18
KR20220097542A (ko) 2022-07-07
US9254338B2 (en) 2016-02-09
CN103533950A (zh) 2014-01-22
US20210121524A1 (en) 2021-04-29
SG10201802789VA (en) 2018-05-30
US11707506B2 (en) 2023-07-25
US10857205B2 (en) 2020-12-08
AU2024204677A1 (en) 2024-07-25
AU2012205599B2 (en) 2016-10-20
KR20200077622A (ko) 2020-06-30
US20210023173A1 (en) 2021-01-28
WO2012097019A1 (en) 2012-07-19
BR112013017752A2 (pt) 2017-08-29
KR20180023015A (ko) 2018-03-06
US11975045B2 (en) 2024-05-07
US12268730B2 (en) 2025-04-08
US11253572B2 (en) 2022-02-22
KR20210030510A (ko) 2021-03-17
KR20260004598A (ko) 2026-01-08
CA2824422A1 (en) 2012-07-19
US20190247463A1 (en) 2019-08-15
KR20190049934A (ko) 2019-05-09
US10130681B2 (en) 2018-11-20
AU2019202260A1 (en) 2019-04-18
MX2013007847A (es) 2013-07-29
JP2019167366A (ja) 2019-10-03
AU2017200290B2 (en) 2019-01-03
EP2663325A1 (en) 2013-11-20
IL260167A (en) 2018-07-31
US20210308217A1 (en) 2021-10-07
US11730794B2 (en) 2023-08-22
US10888601B2 (en) 2021-01-12
US20160101152A1 (en) 2016-04-14
IL227160B (en) 2019-02-28
KR20140043313A (ko) 2014-04-09
SG191334A1 (en) 2013-08-30
KR20240110092A (ko) 2024-07-12
MX349901B (es) 2017-08-18
EP3222285A1 (en) 2017-09-27
IL295359A (en) 2022-10-01
US20210085753A1 (en) 2021-03-25
AU2021200935A1 (en) 2021-03-11
US20210308216A1 (en) 2021-10-07
MX2021006092A (es) 2022-05-18
US20180339018A1 (en) 2018-11-29
MX385629B (es) 2025-03-18
EP3763379A1 (en) 2021-01-13
JP7733706B2 (ja) 2025-09-03
AU2017200290A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
JP7733706B2 (ja) 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
HK40044750A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK40109837A (en) Use of a vegf antagonist to treat angiogenic eye disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161021

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161101

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170322